Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Kathleen Dungan MD, MPH
Kathleen M. Dungan MD, MPH Advisory Board
Silvio Inzucchi MD
Silvio E. Inzucchi MD Editor-in-Chief
Deborah Wexler MD, MSc
Deborah J. Wexler MD, MSc Associate Editor
See All Experts
featured
Published in Diabetes

Expert Opinion / Commentary · November 10, 2015

Two Treatments as Potential Add-Ons to Insulin in Patients With Type 1 Diabetes

Silvio Inzucchi MD

 

 Save  Recommend
 Share

Additional Info

  1. Frandsen CS, Dejgaard TF, Holst JJ, et al. Twelve-Week Treatment With Liraglutide As Add-On to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blinded Parallel Study [published online ahead of print October 20, 2015]. Diabetes Care. doi: 10.2337/dc15-1037.
  2. Henry RR, Thakkar P, Tong C, et al. Efficacy and Safety of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, as Add-On to Insulin in Patients With Type 1 Diabetes [published online ahead of print October 20, 2015]. Diabetes Care. doi: 10.2337/dc15-1730.

Disclosure statements are available on the authors' profiles:

Silvio Inzucchi MD

Further Reading

Most Read This Week

Recently Updated